Amgen Urges No Exceptions To Biosimilar Notice At Fed. Circ.
Amgen is urging the Federal Circuit to rule that biosimilar makers must always give 180-day advance notice of sales to brand-name rivals, arguing that nothing in the Affordable Care Act's approval...To view the full article, register now.
Already a subscriber? Click here to view full article